Figure 6. AZD6244 and Everolimus block tumor growth in-vivo as single agents and in combination.

A. HRAS mutant lung cancer cell line KNS-62 xenografts were treated with AZD6244 (20 mg/kg), or Everolimus 3.5 mg/kg), or a combination of AZD6244 and Everolimus (20 mg/kg and 3.5mg/kg, respectively), or vehicle (DMSO). Each group consisted of 5 mice and tumor volumes (mm³) are shown. Error bars represent standard error values and significance is (* = p < 0.05; ** = p < 0.01). B. Xenografts were explanted at the end of experiments and tumor weight was measured. Significance is (* = p < 0.05; ** = p < 0.01; *** = p < 0.001).